Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...
TMCnet16h
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
Virtual Experience on Tau Pathology At the meeting, Biogen will also host a virtual booth for attendees exploring the role of tau in Alzheimer’s disease, including an interactive medical education ...
'Alzheimer's drugs will come too late for us'
A couple from Hull have called on the government to fund new Alzheimer's drugs, even though they say it will come "too late" ...
Outsourcing-pharma1d
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...
Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...
openaccessgovernment1d
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...
England's Drug-Cost Watchdog Rejects Eli Lilly's Alzheimer's Drug
England's drug-cost regulator rejcted Eli Lilly's Alzheimer's drug for use in the country's public health system, marking the second time a treatment for the disease has been deemed too costly.
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...
STAT1d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Ealing Times1d
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...